Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
14 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/03/14/2845976/0/en/Hyloris-Reports-Full-Year-Results-for-2023-Provides-Business-Outlook.html
14 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/03/14/2845961/0/en/Communication-at-the-request-of-the-FSMA-on-the-transactions-with-Qliniq.html
08 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/03/08/2842882/0/en/Hyloris-to-Report-2023-Full-Year-Results-on-14-March-2024.html
14 Feb 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/02/14/2829330/0/en/Hyloris-Enrolls-First-Patient-in-Phase-3-Clinical-Trial-for-its-Proprietary-Mouth-Rinse-to-Control-Incidences-of-Bleeding-Related-to-Dental-Procedures.html
30 Jan 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/01/30/2819574/0/en/Hyloris-and-Purna-Female-Healthcare-Announce-Positive-Results-from-Phase-2-Trial-in-Patients-with-Acute-Vulvovaginal-Candidiasis-VVC.html
18 Jan 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/01/18/2811837/0/en/Hyloris-Broadens-Pipeline-with-new-Product-Candidate-for-Vulvar-Lichen-Sclerosus-VLS.html
Details:
Combogesic IV (acetaminophen & ibuprofen) is an opioid-free pain relief medicine approved for adults to relieve mild to moderate pain and manage moderate to severe pain as an adjunct to opioids.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Combogesic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Hikma Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Hikma Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Announces Launch of Maxigesic® IV in the U.S. and Approval in Canada
Details : Combogesic IV (acetaminophen & ibuprofen) is an opioid-free pain relief medicine approved for adults to relieve mild to moderate pain and manage moderate to severe pain as an adjunct to opioids.
Brand Name : Combogesic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2024
Details:
Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.
Lead Product(s): Tranexamic Acid
Therapeutic Area: Dental and Oral Health Brand Name: Tranexamic Acid Oral Rinse
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Enrolls First Patient in Phase 3 for Proprietary Mouth Rinse for Dental Bleeding
Details : Tranexamic acid oral rinse is a USFDA approved antifibrinolytic agent, plasminogen inhibitor, which is being evaluatd in phase 3 clinical trials for the treatment of dental bleeding.
Brand Name : Tranexamic Acid Oral Rinse
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Details:
MCZ-DB (miconazole nitrate + domiphen bromide) vaginal cream is being evaluated in phase 2 clinical trials for the treatment of acute vulvovaginal candidiasis.
Lead Product(s): Miconazole Nitrate,Domiphen Bromide
Therapeutic Area: Infections and Infectious Diseases Brand Name: MCZ-DB
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Purna Female Healthcare
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Lead Product(s) : Miconazole Nitrate,Domiphen Bromide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Purna Female Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris and Purna Report Positive Results from Phase 2 Trial in Acute VVC
Details : MCZ-DB (miconazole nitrate + domiphen bromide) vaginal cream is being evaluated in phase 2 clinical trials for the treatment of acute vulvovaginal candidiasis.
Brand Name : MCZ-DB
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 30, 2024
Details:
PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).
Lead Product(s): PTX-252
Therapeutic Area: Oncology Brand Name: PTX-252
Study Phase: UndisclosedProduct Type: Undisclosed
Sponsor: Pleco Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Lead Product(s) : PTX-252
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Pleco Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
U.S. FDA Grants Orphan Drug Designation to PTX-252 for Treating Acute Myeloid Leukemia
Details : PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).
Brand Name : PTX-252
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
January 16, 2024
Details:
HY-029 (valaciclovir) is a viral dna polymerase inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of Herpes Simplex Infections.
Lead Product(s): Valacyclovir
Therapeutic Area: Infections and Infectious Diseases Brand Name: HY-029
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Lead Product(s) : Valacyclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)
Details : HY-029 (valaciclovir) is a viral dna polymerase inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of Herpes Simplex Infections.
Brand Name : HY-029
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 26, 2023
Details:
FDA approved ANDA for Podofilox Gel, a tubulin binder causing cell mitotic arrest, making it ththe first generic topical drug product for the treatment of external genital and perianal warts.
Lead Product(s): Podophyllotoxin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Condylox-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Lead Product(s) : Podophyllotoxin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Announces US FDA Approval for Podofilox Gel
Details : FDA approved ANDA for Podofilox Gel, a tubulin binder causing cell mitotic arrest, making it ththe first generic topical drug product for the treatment of external genital and perianal warts.
Brand Name : Condylox-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 04, 2023
Details:
Maxigesic via intravenous infusion, combines the power of paracetamol and ibuprofen in a unique double-action formulation for fast effective, non-opioid pain relief.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Maxigesic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Announces U.S. FDA Approval of Maxigesic® IV
Details : Maxigesic via intravenous infusion, combines the power of paracetamol and ibuprofen in a unique double-action formulation for fast effective, non-opioid pain relief.
Brand Name : Maxigesic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 18, 2023
Details:
Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Lead Product(s): Lidocaine,Heparin Sodium
Therapeutic Area: Urology Brand Name: Alenura
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Vaneltix Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vaneltix Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)
Details : Alenura is a unique, combination product of alkalinised lidocaine and the glycosaminoglycan heparin. Alkalinised lidocaine penetrates the transitional epithelial cell layer and provides immediate pain relief.
Brand Name : Alenura
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2023
Details:
The funding will be used for the first part of the development of HY-083, a TRPV1 agonist, administered intranasally as a spray, for the treatment of idiopathic rhinitis.
Lead Product(s): HY-083
Therapeutic Area: Immunology Brand Name: HY-083
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Walloon Region
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 08, 2023
Lead Product(s) : HY-083
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Walloon Region
Deal Size : $1.0 million
Deal Type : Funding
Hyloris has been Granted EUR 1 Million in Non-Dilutive Funding from the Walloon Region
Details : The funding will be used for the first part of the development of HY-083, a TRPV1 agonist, administered intranasally as a spray, for the treatment of idiopathic rhinitis.
Brand Name : HY-083
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 08, 2023
Details:
Maxigesic® via intravenous infusion, combines the power of paracetamol and ibuprofen in a unique double-action formulation for fast effective, non-opioid pain relief.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Maxigesic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyloris Announces Submission of Maxigesic® IV Packaging Data Requested by The US FDA
Details : Maxigesic® via intravenous infusion, combines the power of paracetamol and ibuprofen in a unique double-action formulation for fast effective, non-opioid pain relief.
Brand Name : Maxigesic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 18, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?